Clinical trials: LOCALLY ADVANCED RECTAL CANCER
Solid Tumor
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
- Trial name
- LODESTAR (NCT04171700)
- Testing
- Rucaparib
- Where
- 19 sites in United States
- Volunteers
- 83 people
- Sponsor
- pharmaand GmbH
Rectal Cancer
Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen
This study is designed to test the efficacy and safety of Total Neoadjuvant Treatment plus SHR1210（an anti-PD-1 Inhibitor) for High-risk locally advanced Rectal Cancer, Meanwhile, screening effective Biomarker base on neoantigen.
- Trial name
- NCT04340401
- Testing
- SHR-1210, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking University Cancer Hospital & Institute
Locally Advanced Rectal Cancer
TIME in Immunotherapy Combined With nCRT for Rectal Cancer
This is an open-label, prospective phase II clinical trial to evaluate the therapeutic and prognostic implications of tumor immune microenvironment in the neoadjuvant immunotherapy combined with chemoradiotherapy for patients…
- Trial name
- TIMENT-R (NCT05507112)
- Testing
- PD-1 inhibitor, Capecitabine, Long-course radiation therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Colorectal Cancer
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic…
- Trial name
- DESTINY-CRC02 (NCT04744831)
- Testing
- DS-8201a 5.4 mg/kg Q3W, DS-8201a 6.4 mg/kg Q3W
- Where
- 63 sites in United States, Australia and 8 more
- Volunteers
- 122 people
- Sponsor
- Daiichi Sankyo
Solid Tumor, Adult, Solid Tumor
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- EVEREST-1 (NCT05736731)
- Testing
- A2B530, xT-Onco with HLA-LOH Assay
- Where
- 8 sites in United States
- Volunteers
- 160 people
- Sponsor
- A2 Biotherapeutics Inc.
Rectal Cancer
Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance
After signing the informed consent form, patients who met the inclusion and exclusion criteria were given the full course of neoadjuvant treatment: short-term radiotherapy, followed by 6 consecutive cycles of disitamab vedotin…
- Trial name
- NCT07509424
- Testing
- disitamab vedotin, sintilimab, capecitabine
- Volunteers
- 29 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colorectal Neoplasms
Locally Advanced Colorectal Cancer and Local Recurrences in Västra Götaland
The aim of this study is to review the treatment strategies of locally advanced colorectal cancer and locally recurrent rectal cancer in Västra Götaland during 1995-2016.
- Trial name
- NCT04406974
- Testing
- Surgery or treatment for local recurrence, Surgery for advanced colorectal cancer
- Where
- Sweden
- Volunteers
- 4,000 people
- Sponsor
- Sahlgrenska University Hospital
Colorectal Cancer
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects.
- Trial name
- NCT01133990
- Testing
- FOLFIRI, E7820, Bevacizumab
- Where
- 34 sites in United States, Australia and 3 more
- Volunteers
- 5 people
- Sponsor
- Eisai Inc.
Rectal Adenocarcinoma
A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the efficacy and safety of short-course radiotherapy followed by ivonescimab and chemotherapy in participants with pMMR/MSS locally advanced rectal cancer.
- Trial name
- NCT06919510
- Testing
- lvonescimab, CAPOX (oxaliplatin/capecitabine), radiotherapy
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Carcinoma
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer
The goal of this clinical trial is to compare the efficacy and safety of neoadjuvant chemoradiotherapy combined with tirelizumab compared with neoadjuvant chemoradiotherapy alone for neoadjuvant therapy in patients with locally…
- Trial name
- NCT06312982
- Testing
- Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 375 people
- Sponsor
- Beijing Friendship Hospital
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
Anal Cancer, Locally Advanced Squamous Cell Carcinoma
Circulating Biomarkers in Patients With Anal Cancer Treated With Induction Chemotherapy
To investigate the prognostic and predictive value of plasma HPV (pHPV) prior, during and after induction chemotherapy (ICT) in locally advanced squamous cell carcinoma of the anus (SCCA) or synchronous metastatic SCCA patients…
- Conditions
- Anal Cancer, Locally Advanced Squamous Cell Carcinoma, Oligometastatic Disease, Circulating Tumor Cell
- Trial name
- NCT05233540
- Where
- 3 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Aarhus University Hospital
Melanoma, Non-Small Cell Lung Cancer
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in…
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT03289962
- Testing
- Autogene cevumeran, Atezolizumab
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 273 people
- Sponsor
- Genentech, Inc.
Locally Advanced Rectal Cancer (LARC)
Development and Validation of a Post-operative Risk Of Local Recurrence Model Integrating Serology and Evalution (PROMISE) in Local Advanced Rectal Cancer Receiving Neoadjuvant Therapy: a Multicenter Study
Local recurrence (LR) in locally advanced rectal cancer (LARC) correlated with poor survival and impaired quality of life. The aim of this study was to develop and validate machine learning (ML) models integrating…
- Trial name
- PROMISE model (NCT07351708)
- Volunteers
- 2,315 people
- Sponsor
- Cai Zerong
Anal Cancer
Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00955240
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 20 sites in France
- Volunteers
- 16 people
- Sponsor
- UNICANCER
Locally Advanced Rectal Cancer
Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer
To investigate dynamic change of gut microbiomes and metabolites, and their effects on immune modulation. To evaluate the efficacy and safety of TNT with GEN-001 (Lactococcus lactis) and identify predictive biomarkers for…
- Trial name
- NCT05079503
- Testing
- GEN-001
- Volunteers
- 40 people
- Sponsor
- Korean Cancer Study Group
Mid-low Rectal Cancer
Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer
To explore the complete response (CR) rate of modified short-course radiotherapy combined with CAPOX and tislelizumab for locally Advanced Mid-low Rectal Cancer
- Trial name
- NCT06333769
- Testing
- Short-course Radiotherapy, Tislelizumab, Capecitabine
- Where
- 3 sites in China
- Volunteers
- 38 people
- Sponsor
- Fujian Cancer Hospital
Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
Previously, preliminary results, from a subgroup analysis of STARS-RC03 (NCT04906044) conducted by our research team, showed that the 6-cycles consolidation chemotherapy combining with anti-PD-1 therapy had a better tumor…
- Conditions
- Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1
- Trial name
- NCT05998122
- Testing
- nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Hospital of Jilin University
Rectal Cancer
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer
Multimodality treatment that comprises preoperative fluoropyrimidine with concurrent radiotherapy followed by total mesorectal excision (TME) surgery and adjuvant fluoropyrimidine-based chemotherapy is recommended as a standard…
- Trial name
- FOBEAR (NCT04215731)
- Testing
- Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab, Restaging, Concomitant Chemoradiotherapy
- Where
- China
- Volunteers
- 582 people
- Sponsor
- Yanhong Deng
Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX), may help participants with rectal cancer.
- Conditions
- Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma, HER2 Positive Rectal Adenocarcinoma
- Trial name
- NCT05672524
- Testing
- Trastuzumab, Tucatinib
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center